MAZE (Maze Therapeutics) Ending Cash Position: $203.73 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MAZE Maze Therapeutics Inc MAZE
16 GF Score
Price $27.20
! 3 Warning Signs
View Full Analysis

What is Maze Therapeutics Ending Cash Position?

Maze Therapeutics MAZE -1.63% 16 Ending Cash Position is $203.73 Mil as of Jun. 2026. GuruFocus rates MAZE with a GF Score™ of 16/100. The stock has 3 warning signs investors should review.

Maze Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 was $203.73 Mil.

Maze Therapeutics's quarterly Ending Cash Position increased from Dec. 2025 ($190.34 Mil) to Mar. 2026 ($199.85 Mil) and increased from Mar. 2026 ($199.85 Mil) to Jun. 2026 ($203.73 Mil).

Maze Therapeutics's annual Ending Cash Position increased from Dec. 2023 ($30.25 Mil) to Dec. 2024 ($197.90 Mil) but then declined from Dec. 2024 ($197.90 Mil) to Dec. 2025 ($190.34 Mil).

Maze Therapeutics Ending Cash Position Related Terms

Maze Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Maze Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maze Therapeutics Ending Cash Position Chart

Maze Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Ending Cash Position
101.13 30.25 197.90 190.34

Maze Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 265.63 317.86 190.34 199.85 203.73
MAZE
16GF Score
Maze Therapeutics Inc MAZE
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maze Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Maze Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=197.9+-7.565
=190.34

Maze Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=199.854+3.877
=203.73

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $203.73 Mil mean?
Maze Therapeutics (MAZE) has a Ending Cash Position of $203.73 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Maze Therapeutics and its competitors.
Is Maze Therapeutics' Ending Cash Position too high?
Maze Therapeutics' current Ending Cash Position is $203.73 Mil. Overall, Maze Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' Ending Cash Position compare to NTLA and RXRX?
Maze Therapeutics' Ending Cash Position of $203.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Maze Therapeutics and its competitors. Maze Therapeutics's current Ending Cash Position is $203.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current Ending Cash Position of $203.73 Mil. The current Ending Cash Position is $203.73 Mil. Maze Therapeutics' overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current Ending Cash Position is $203.73 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Maze Therapeutics Business Description

Address 171 Oyster Point boulevard, Suite 300, South San Francisco, CA, USA, 94080
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
16GF Score

Get the complete analysis for MAZE

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.20
Price